INS and type 2 diabetes mellitus: Nevertheless, the similarity in results between the present NMA and Soli‐D may suggest that, at least qualitatively, the clinical benefits of iGlarLixi versus IDegAsp are observed in both insulin‐naïve and insulin‐experienced populations with T2D.